Navigation Links
Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
Date:5/16/2008

herapeutic agents by increasing drug circulation time, improving pharmacokinetics, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability.

"The impressive Phase 1 results with NKTR-102 represent a major advancement for our small molecule PEGylation platform," said Howard W. Robin, President and CEO of Nektar. "Using our proprietary technology, Nektar is the first company to create a PEGylated small molecule with a unique pharmacokinetic profile that has demonstrated therapeutic activity in patients. This pioneering success with NKTR-102 validates our platform and opens the door to a wide range of potential small molecule opportunities. "

Clinical Trial Summary

In the Phase 1 dose-escalation trial, the safety, pharmacokinetics and anti-tumor activity of NKTR-102 monotherapy was evaluated in patients with refractory solid tumors. Patients received 90-minute infusions of NKTR-102 (PEGylated irinotecan) repeated as follows: weekly for three weeks with the fourth week off; every two weeks; or every three weeks. Tumor responses are being evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria.

In the first dose schedule (weekly x3 q4 weeks), NKTR-102 was administered to a total of 32 patients with advanced solid tumors who had failed prior treatments or had no standard treatment available to them. Doses ranged from 58 mg/m2 to 230 mg/m2. Tumor regression, anti-tumor activity or prolonged disease stabilization was observed in a number of cancer types, including non- small cell lung cancer, ovarian, small cell lung cancer, cervical, adrenocortical, esophageal, and Hodgkin's lymphoma.

Results from the second and third dose schedules of this Phase 1 trial will be presented by featured speaker, Dr. Daniel D. Von Hoff, at an investor event on June 2, 2008. The Webcast event will begin at 6 pm Central time and will occur during the American Society of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Luoxis Diagnostics, Inc. ... (NYSE MKT: AMPE), today announced an upcoming ... of the American Academy of Surgical Trauma (AAST) ... Philadelphia, Pennsylvania that will ... report results from a recently completed five-year prospective ...
(Date:8/18/2014)... Japan , Aug. 19, 2014 Boston ... INTECC (Securities Code 7747, Second Section, Tokyo ... to develop a new, differentiated fractional flow reserve (FFR) ... intended to improve handling compared to existing FFR wires. ... in interventional cardiology that exceeds $250 million worldwide and ...
(Date:8/18/2014)... , Aug. 18, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p01597713/Bioseparation-Systems-for-Global-Biopharmaceutical-Markets.html ... into three types: chromatography, membranes/filters and centrifuges. ... increasing and fueling growth of the global ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
(Date:8/20/2014)... B. E. Smith, the only full-service ... been retained to lead a national chief operating ... in Hermiston, Ore. The top executive search firm ... recently placed more than 900 healthcare executives into organizations. ... progressive, not-for-profit healthcare organization serving a population of more ...
(Date:8/20/2014)... 2014 Biosimilars, which are similar ... through an abbreviated process, could reap billions in ... Information Services, Inc.’s (AIS) Specialty Pharmacy News offers ... the Food and Drug Administration’s (FDA) recent acceptance ... approval. , Drugmaker Sandoz said July 24 that ...
(Date:8/20/2014)... 20, 2014 Building on growing ... successfully predicted stage iii and iv pressure ulcers ... situations, approached 90%. A company spokesperson commented that ... commercial or academic settings. The resulting capabilities can ... of hospital-acquired conditions to help providers avoid financial ...
(Date:8/20/2014)... August 20, 2014 BuyCheapTicketsToEvents.com is ... wide selection of tickets to many events. Cheap NHL hockey ... begin in September. , Hockey fans are enthusiastic about their ... tickets for games. Now is the time to acquire 2014 ... in mere months. There will be a great deal of ...
(Date:8/20/2014)... The “Human Insulin Market by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2019” provides a ... current market trends,and strategies impacting the global human ... of the revenue and share analysis. , Browse ...
Breaking Medicine News(10 mins):Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4
... , , , WOBURN, ... died Wednesday, August 12, 2009 at Massachusetts General Hospital in Boston. Doctors say ... 55 years old. , , Dr. Gilbard is best known ... condition that is caused by a chronic lack of moisture in the eye. ...
... , HATBORO, Pa., Aug. 13 InfoLogix, Inc. (Nasdaq: ... the healthcare and commercial industries, today announced financial results for the quarter ... http://www.newscom.com/cgi-bin/prnh/20090618/NE3513 5 LOGO ) , ... , David T. Gulian, president and chief executive officer ...
... uncertain, researchers say , THURSDAY, Aug. 13 (HealthDay News) ... out and destroy the stem cells that scientists believe ... growing body of research is showing that cancer stem ... causing cancer to reappear even after treatment seems to ...
... , , MECHANICSBURG, Pa., Aug. 13 ... quarter ended June 30, 2009. , , ... revenues increased 3.8% to $559.5 million compared to $538.8 million ... increased 35.0% to $65.4 million compared to $48.4 million for ...
... , , , ... CRDC ) today reported financial results and corporate progress for ... , , "With a slower than expected ... fiscal fourth quarter we had to make difficult decisions to revise ...
... , U.S. Rep. Barbara Lee (D-Calif.) Also to be ... The intensifying debate about health care reform in America will be addressed this ... Aug. 14 at 10 a.m. EDT nationwide on Federal News Radio at ... Washington , D.C. , area. , , ...
Cached Medicine News:Health News:Ophthalmology Pioneer Dr. Jeffrey P. Gilbard Dies 2Health News:Ophthalmology Pioneer Dr. Jeffrey P. Gilbard Dies 3Health News:InfoLogix Announces Second Quarter Financial Results 2Health News:InfoLogix Announces Second Quarter Financial Results 3Health News:InfoLogix Announces Second Quarter Financial Results 4Health News:InfoLogix Announces Second Quarter Financial Results 5Health News:InfoLogix Announces Second Quarter Financial Results 6Health News:InfoLogix Announces Second Quarter Financial Results 7Health News:InfoLogix Announces Second Quarter Financial Results 8Health News:Compound Targets, Destroys Cancer Stem Cells in Mice 2Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 2Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 3Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 4Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 5Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 6Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 7Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 8Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 9Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 10Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 11Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 12Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 13Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 14Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 15Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 2Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 3Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 4Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 5Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 6Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 8Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 9Health News:Health Care Reform to be Discussed on 'Inside Government' 2
... reads, writes and prints "Smart" labels. As ... or barcode on the label surface. SATO's ... a range of applications, including: Compliance Labeling, ... Tagging, Retail Labeling, Product Authentication. CL408e RFID ...
... is a core software component ... which enables location-based applications in ... capabilities of the AeroScout Engine ... management of AeroScout hardware and ...
... The Kisses tag is part ... of the Hugs system. The Kisses ... mother after it has been bonded ... her baby. he two tags remain ...
... Radianse active-RFID-tags can be ... For example, that a device ... complete or that a patient ... Every message from an ID-tag ...
Medicine Products: